Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Albumin used in human IVF contain different levels of lipids and modify embryo and fetal growth in a mouse model|
|Citation:||Journal of Assisted Reproduction and Genetics, 2021; 38(9):1-10|
|Publisher:||Springer Science and Business Media LLC|
|Deirdre Zander-Fox, Lauren Villarosa, Nicole O. McPherson|
|Abstract:||Purpose Different commercial human embryo culture mediums can alter embryo quality and change birthweight. One component that could be contributing to variations but is not widely investigated is human serum albumin (HSA). HSA plays a multitude of roles during embryo culture and is a carrier for molecules including lipids. It remains unclear if lipid composition of HSA varies among commercial products and its effects on embryo quality, implantation, and fetal outcomes are relatively unknown. Methods Utilizing a mouse model of embryo culture, we cultured zygotes until the blastocyst stage (72-h culture) in G1/G2 containing either Vitrolife HSA, Sage HSA, or Recombinant HSA at 10%. Blastocyst quality (development, total cell number, superoxide generation), blastocyst lipid content (neutral lipids, non-esterified fatty acids, phospholipids, and triglycerides), implantation, and fetal lengths and weights were assessed. Fatty acid quantification of HSA source was assessed by standard thin-layer chromatography. Results Sage HSA had the greatest fatty acid composition, with an eightfold increase in saturated fatty acids. This coincided with reduced blastocyst development, increased superoxide generation, neutral lipids and triglycerides levels of blastocysts, and decreased implantation rates (p < 0.05). Unexpectedly, while Recombinant HSA had the lowest overall lipids it had 70-fold increase in palmitoleic acid and the lowest fetal weights (p < 0.05). Conclusion Indicates the importance of a balance between different types/amount of lipids, and an “optimal ratio” required for embryo and fetal development. Therefore, the lipid content of HSA should be considered when choosing a suitable HSA source for use in clinical IVF.|
|Keywords:||In vitro fertilization; assisted reproduction technology; blastocyst; fetal weight; fatty acids|
|Rights:||© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.